Liquidia Corporation Common Stock (LQDA) — 分析摘要
Liquidia Corporation Common Stock（LQDA）的市值为5.85十亿美元，最近一年的营收同比增长了+1031.2%。净利润率为-43.5%。当前市盈率为42.2倍。
核心要点
- 营收同比变化+1031.2%
- 净利润率-43.5%
- 市盈率42.2倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，LQDA的营收增长为+1031.2%，市盈率为42.2倍。
Liquidia Corporation Common Stock (LQDA)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
营业利润率 (37.4%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
216
总部
MORRISVILLE, NC
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。